Tyrnovo Ltd.

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.tyrnovo.co.il

Clinical Trials

1

Active:1

Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1

1 (100.0%)

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Colorectal Adenocarcinoma
Head and Neck Cancer
Solid Tumor, Adult
Metastatic Solid Tumor
Recurrent Solid Tumor

Interventions: Drug: NT219
Drug: NT219 and ERBITUX® - Dose Escalation
Drug: NT219 and ERBITUX® - Expansion

First Posted Date: 2020-07-16

Last Posted Date: 2024-05-09

Lead Sponsor: TyrNovo Ltd.

Target Recruit Count: 110

Registration Number: NCT04474470

Locations: 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States

and more 7 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.